Clinical Trial Update: Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial of veliparib with cisplatin and gemcitabine in advanced biliary tract, pancreatic, urothelial, and non-small cell lung cancers was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Bladder Cancer
• Hepatocellular Carcinoma
• Non-small Cell Lung Cancer
• Pancreatic Cancer
• Urothelial Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemcitabine hydrochloride (Gemcitabine hydrochloride)
• Veliparib (veliparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer | Phase 1 | Status: TERMINATED